Premium
Evaluation on a S treptococcus suis Vaccine Using Recombinant S ao‐ L Protein Manufactured by Bioreactors as the Antigen in Pigs
Author(s) -
Hsueh K.J.,
Lee J.W.,
Hou S.M.,
Chen H.S.,
Chang T.C.,
Chu C.Y.
Publication year - 2014
Publication title -
transboundary and emerging diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.392
H-Index - 63
eISSN - 1865-1682
pISSN - 1865-1674
DOI - 10.1111/tbed.12067
Subject(s) - streptococcus suis , serotype , antigen , microbiology and biotechnology , recombinant dna , biology , virology , immunization , antibody , bacteria , virulence , immunology , gene , biochemistry , genetics
Summary Streptococcus suis ( S. suis ) can be classified into 33 serotypes based on the structure of capsular polysaccharides. Recent research indicated that a new surface protein designated as S ao (surface antigen one) reacts with 30 serotypes of convalescent‐phase sera during S. suis infections, which makes Sao a good potential antigen for developing S. suis vaccines. The objectives of this study were to produce recombinant Sao‐ L protein ( rS ao‐L) from a strain of S. suis serotype 2 by a prokaryotic expression system in bioreactors and to use rS ao‐ L as the antigen for a S. suis vaccine in mouse and swine models. The antibody titres in mice and pigs immunized with rS ao‐ L were significantly ( P < 0.05) increased. After challenge with live S. suis serotype 1 bacteria, the anatomical lesions in pigs immunized with rS ao‐L were reduced by 60%. These data indicated that immunization with rS ao‐ L can confer cross‐serotype protection against S. suis . Moreover, percentages of CD 8 + and CD 4 + / CD 8 + double‐positive T cells in immunized pigs were significantly higher than those of the control group ( P < 0.01). Using bioreactors to produce rS ao‐ L as the antigen for S. suis vaccines may broaden protective efficacy and reduce production costs.